Detection of early-stage lung adenocarcinoma using a novel extracellular vesicle and particle-based blood test.
A blood test using four cancer markers shows promise for catching early lung cancer, with accuracy improving as tumors grow larger.
Mercy BioAnalytics developed a proximity ligation immunoassay that detects four co-localized cancer-associated biomarkers on tumor-derived EVPs in plasma, demonstrating that requiring four coincident markers substantially reduces background from healthy tissue EVPs compared to three-marker designs. While stage I sensitivity of 48.5% is modest, the approach shows a clear dose-response with stage and tumor size, with commercial and analytical validation work needed before clinical application.
What the study was
- Study design
- case_control_proof_of_concept
- Population
- Lung adenocarcinoma cases and healthy controls
- Sample size
- 382 (92 cases, 290 controls)
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Scientific Reports
Why it surfaced
Novel EVP-based analyte class with mechanistically sound design; addressing the key specificity limitation of liquid biopsy; stage II/III sensitivity metrics are clinically promising; industry-sponsored (Mercy BioAnalytics) with patent portfolio signals commercialization intent.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.